A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Prior treatment

• The toxicity of previous anti-tumor therapy has not been alleviated；

Other illness

• History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
• Evidence and history of severe bleeding tendency;
• History of severe cardiovascular diseases within 6 months;
• History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;
• History of alcohol abuse, psychotropic substance abuse or drug abuse;
• Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;
• Other conditions considered unsuitable for this study by the investigator.

Lab values

• Have received anti-platelet therapy within 10 days prior to the first dose of the study drugs;

Other

• Histologically or cytologically confirmed mixed SCLC;
• Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
• Pregnant or lactating women;

• Signed informed consent form before any trial-related processes;
• Age ≥18 years;
• Histologically or cytologically confirmed ES-SCLC;
• No prior systemic therapy for ES-SCLC;
• Have adequate organ function;
• The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;
• Life expectancy of ≥12 weeks;
• Had at least one measurable tumor lesion according to RECIST v1.1.